RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Apr 3

PMID 33799422

Citations 9

Authors

Areti Strati

Michail Nikolaou

Vassilis Georgoulias

Evi S Lianidou

Affiliations

Soon will be listed here.

Abstract

In metastatic breast cancer (MBC) the molecular characterization of circulating tumor cells (CTCs) provides a unique tool to understand metastasis-biology and therapy-resistance. We evaluated the prognostic significance of gene expression in EpCAM CTCs in 46 MBC patients based on a long follow-up. We selected a panel consisting of stem cell markers (, , ), the mesenchymal marker , receptors (, , , ) and the epithelial marker . Singleplex RT-qPCR was used for and and multiplex RT-qPCR for stem cell markers and receptors. A group of 19 healthy donors (HD) was used as control. Univariate ( = 0.001) and multivariate analysis ( = 0.002) revealed the prognostic value of combined gene expression of (+), , and over-expression for overall survival (OS). The Kaplan-Meier estimates of OS were significantly different in patients positive for ( = 0.028), ( = 0.002), ( = 0.007) and -positive ( = 0.022). Our results indicate that combined gene expression analysis in EpCAM CTCs provides prognostic information in MBC.

Citing Articles

Circulating Tumor Cells: Origin, Role, Current Applications, and Future Perspectives for Personalized Medicine.

Rapanotti M, Cenci T, Scioli M, Cugini E, Anzillotti S, Savino L Biomedicines. 2024; 12(9).

PMID: 39335650 PMC: 11429165. DOI: 10.3390/biomedicines12092137.

Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis.

Zhang Z, Bao Y, Zhao Y, Wang J, Guo J, Sun S World J Clin Oncol. 2023; 14(11):504-517.

PMID: 38059182 PMC: 10696218. DOI: 10.5306/wjco.v14.i11.504.

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management.

Keup C, Kimmig R, Kasimir-Bauer S Cancers (Basel). 2023; 15(22).

PMID: 38001722 PMC: 10670968. DOI: 10.3390/cancers15225463.

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.

Strati A, Markou A, Kyriakopoulou E, Lianidou E Cancers (Basel). 2023; 15(7).

PMID: 37046848 PMC: 10092977. DOI: 10.3390/cancers15072185.

Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines.

Pham S, Griffiths L, Okolicsanyi R, Haupt L Data Brief. 2023; 46:108880.

PMID: 36687151 PMC: 9852922. DOI: 10.1016/j.dib.2022.108880.

References

Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M . Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015; 26(9):1859-1865. PMC: 4551160. DOI: 10.1093/annonc/mdv282. View

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M . Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008; 14(9):2593-600. DOI: 10.1158/1078-0432.CCR-07-4758. View

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

Bouris P, Skandalis S, Piperigkou Z, Afratis N, Karamanou K, Aletras A . Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015; 43:42-60. DOI: 10.1016/j.matbio.2015.02.008. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N . A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer. 2006; 119(7):1654-9. DOI: 10.1002/ijc.22017. View

Beije N, Onstenk W, Kraan J, Sieuwerts A, Hamberg P, Dirix L . Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 2016; 18(11):647-653. PMC: 5071539. DOI: 10.1016/j.neo.2016.08.007. View

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A . Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Clin Cancer Res. 2017; 24(6):1500-1510. DOI: 10.1158/1078-0432.CCR-17-1181. View

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K . Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res. 2011; 13(3):R60. PMC: 3218949. DOI: 10.1186/bcr2897. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Keup C, Mach P, Aktas B, Tewes M, Kolberg H, Hauch S . RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. Clin Chem. 2018; 64(7):1054-1062. DOI: 10.1373/clinchem.2017.283531. View

12.

Ignatiadis M, Sledge G, Jeffrey S . Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5):297-312. DOI: 10.1038/s41571-020-00457-x. View

13.

Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C . Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009; 118(3):523-30. DOI: 10.1007/s10549-009-0461-7. View

14.

Jakabova A, Bielcikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U . Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. Breast Cancer Res Treat. 2017; 166(3):695-700. PMC: 5680374. DOI: 10.1007/s10549-017-4452-9. View

15.

Vincent Jordan N, Bardia A, Wittner B, Benes C, Ligorio M, Zheng Y . HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016; 537(7618):102-106. PMC: 5161614. DOI: 10.1038/nature19328. View

16.

Kallergi G, Agelaki S, Papadaki M, Nasias D, Matikas A, Mavroudis D . Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 2015; 17:113. PMC: 4541732. DOI: 10.1186/s13058-015-0624-x. View

17.

Lang J, Scott J, Wolf D, Novak P, Punj V, Magbanua M . Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2014; 149(1):121-31. PMC: 4698170. DOI: 10.1007/s10549-014-3215-0. View

18.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G . Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012; 23(7):1744-50. DOI: 10.1093/annonc/mds020. View

19.

Reijm E, Sieuwerts A, Smid M, Vries J, Mostert B, Onstenk W . An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer. 2016; 16:123. PMC: 4759736. DOI: 10.1186/s12885-016-2155-y. View

20.

Aaltonen K, Novosadova V, Bendahl P, Graffman C, Larsson A, Ryden L . Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget. 2017; 8(28):45544-45565. PMC: 5542207. DOI: 10.18632/oncotarget.17271. View